Loading
companiesCompany
Genesis Molecular AI (formerly Genesis Therapeutics)
Genesis Molecular AI does small-molecule discovery on its GEMS platform, which combines physics and deep learning, with oncology programmes in the clinic pipeline.
Overview
Genesis Molecular AI, formerly Genesis Therapeutics and based in Burlingame, California, does small-molecule discovery on its GEMS platform, which combines physics and deep learning, with oncology programmes in its clinic-bound pipeline. It holds partnerships with Genentech, Lilly, Gilead and Incyte and rebranded in 2025. OnCo links it to AI-driven drug and target discovery. Whether physics-informed models find small molecules for targets that conventional screening missed is the question its pipeline will answer. The AI-driven drug discovery page carries the wider field.
Similar pages
- CompanyIambic Therapeutics
Shares AI-driven drug & target discovery and the tag ai.
- CompanyLila Sciences
Shares AI-driven drug & target discovery and the tag ai.
- CompanyCradle
Shares AI-driven drug & target discovery and the tag ai.
- CompanyLatent Labs
Shares AI-driven drug & target discovery and the tag ai.
- CompanyProfluent
Shares AI-driven drug & target discovery and the tag ai.
- TechnologyChemistry42 and Pharma.AI (Insilico)
Shares AI-driven drug & target discovery and the tag ai.
- PersonRegina Barzilay
Shares AI-driven drug & target discovery and the tag ai.